Intimation of completion of US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.

August 28, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Completion of US FDA Inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company – Reg., Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that – The United States Food and Drug Administration (US FDA) inspected Unit-VI, an API manufacturing facility of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at E-Bonangi Village, Parawada Mandal, Anakapalli District, 531019, Andhra Pradesh from August 24 to August 28, 2026. We wish to inform you that the inspection concluded with three observations, which are procedural in nature, and we will respond to the US FDA within the stipulated timeline. The Company is committed to maintaining robust quality and compliance standards across its manufacturing facilities. The Company will keep the Stock Exchanges informed of any further developments in this regard, as required under the applicable regulations. Please take the above information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com